The Focused Ultrasound Foundation recognizes that the intersection of focused ultrasound and cancer immunotherapy offers a highly promising opportunity for combination approaches to treat a variety of cancers. Through our Cancer Immunotherapy Program and collaboration with our partners and the research community, we aim to explore and assess the full potential of focused ultrasound to turn this promise into reality.
It’s been five years since the Foundation formally launched our Cancer Immunotherapy Program. Now, as the Cancer Research Institute’s 8th annual Cancer Immunotherapy Month™ comes to a close, we are pleased to highlight important progress that has been made in the field and key Foundation activities in this flagship program. Our efforts have helped push the field forward, and we continue to work diligently toward a future immune to cancer.
Jill O’Donnell-Tormey, PhD, CEO of the Cancer Research Institute (CRI), and the Foundation's Chief Scientific Officer, Jessica Foley, PhD, discuss cancer immunotherapy and the ways that CRI and the Foundation are working together to advance exciting research, through a lens of the COVID-19 environment (60 minutes).
Kelsie Timbie, PhD, Scientific Programs Manager and Veterinary Program Director, provides an introduction to how the fields of focused ultrasound and cancer immunotherapy intersect (8 minutes).
New and ongoing clinical and preclinical research is examining the use of focused ultrasound in initiating an anti-tumor immune response – either alone or in combination with immunotherapies – to treat cancer.
The Foundation’s scientific team has drafted guidelines outlining high priority immune assays for preclinical and clinical studies to help standardize research in this area. We are inviting public comment on these documents until August 1, 2020.
In recognition of the 8th annual Cancer Immunotherapy Month™, the Foundation coordinated with the Cancer Research Institute throughout June to help raise awareness of immunotherapy for all types of cancer and emphasize the role of focused ultrasound.
James P. Allison, PhD, Chair of Immunology at MD Anderson Cancer Center, will share three decades of experience studying cancer immunotherapies. His documentary “Breakthrough” chronicles how his visionary immunology research revolutionized cancer treatment and earned him the Nobel Prize.
Through our Cancer Immunotherapy Funding Program, the Foundation offers research funding alone and in conjunction with its partners. Over the past four years, we have funded 20 studies that range from preclinical through translational to clinical trials on all types of cancer models.
We use cookies to optimize our website and our service.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
By using FUSF’s AI agent, you acknowledge and agree that your use is governed by FUSF’s Terms of Use Agreement. If you do not agree to be bound by the Terms of Use Agreement, you may not access or use FUSF’s AI agent.
